brand logo

Am Fam Physician. 2008;77(8):1078-1079

Author disclosure: Nothing to disclose.

Original Article: Treatment Options for Actinic Keratoses

Issue Date: September 1, 2007

to the editor: The article in American Family Physician is a comprehensive review of the available therapeutic options for patients with actinic keratoses. Although the article illustrates useful recommendations for actinic keratoses, we would like to make some clarifications and suggest further treatments.

Actinic cheilitis is a clinical variant of actinic keratoses developing typically on the lower lip (the more sunexposed area), which has a greater risk of progression to invasive squamous cell carcinoma compared with normal skin.1 Early actinic, keratotic lesions of the lips may have a rough contour and/or appear slightly white (milky discoloration). More advanced lesions appear erythematous, thickened, and may show fissuring, scaliness, or ulcerations (Figure 1A) with loss of the vermilion border.1 Any suspicious thickened, ulcerated, or cryotherapy-resistant lesions should be biopsied first; we advise using the shave technique to avoid scarring.2

Treatment options for actinic cheilitis include emollients, electrosurgery, cryotherapy (Figure 1B), 5-fluorouracil, photodynamic therapy, curettage, excision, lasers, and occasionally, radiotherapy. The use of a prophylactic sunscreen containing lip pomade slows the rate of development of solar lesions and protects the skin from further damage.2 Carbon dioxide laser treatment of actinic cheilitis is a highly effective option for extensive lesions and usually results in minimal recurrence with excellent cosmetic results.3

Topical 5-fluorouracil is preferable for patients with multiple thin lesions, for whom the use of cryotherapy or other more aggressive treatments would cause unwanted aesthetic results.4 Photodynamic therapy using 5-aminolevulinic acid5 can lead to satisfactory outcomes. Other options include topical therapy with diclofenac 3% gel (Solaraze) or imiquimod 5% (Aldara). The optimal dose and duration of topical therapies, as well as their long-term effectiveness, need to be established in large prospective studies.

Email letter submissions to afplet@aafp.org. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors. Letters submitted for publication in AFP must not be submitted to any other publication. Letters may be edited to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, deputy editor.

Continue Reading


More in AFP

More in Pubmed

Copyright © 2008 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.